TN2013000220A1 - Orally disintegrating tablet - Google Patents

Orally disintegrating tablet

Info

Publication number: TN2013000220A1
Authority: TN; Tunisia
Prior art keywords: fine granules; active ingredient; pharmaceutically active; lansoprazole; controlled release
Prior art date: 2010-12-27

Application number

TNP2013000220A

Other languages

English (en)

Inventor

Shiro Ishii

Yutaka Ebisawa

Takayuki Okabe

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-27

Filing date

2013-05-24

Publication date

2014-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45509604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000220(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-05-24 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2014-11-10 Publication of TN2013000220A1 publication Critical patent/TN2013000220A1/fr

Links

239000006191 orally-disintegrating tablet Substances 0.000 title abstract 3
239000008187 granular material Substances 0.000 abstract 8
239000004480 active ingredient Substances 0.000 abstract 6
229920001577 copolymer Polymers 0.000 abstract 4
238000013270 controlled release Methods 0.000 abstract 3
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 abstract 3
229960003174 lansoprazole Drugs 0.000 abstract 3
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract 2
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 abstract 2
239000011247 coating layer Substances 0.000 abstract 2
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 abstract 2
229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
230000000996 additive effect Effects 0.000 abstract 1
229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 abstract 1
229960003943 hypromellose Drugs 0.000 abstract 1
210000000214 mouth Anatomy 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP2013000220A 2010-12-27 2013-05-24 Orally disintegrating tablet TN2013000220A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201061427384P	2010-12-27	2010-12-27
PCT/JP2011/080568 WO2012091153A2 (fr)	2010-12-27	2011-12-26	Comprimé orodispersible

Publications (1)

Publication Number	Publication Date
TN2013000220A1 true TN2013000220A1 (en)	2014-11-10

Family

ID=45509604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000220A TN2013000220A1 (en)	2010-12-27	2013-05-24	Orally disintegrating tablet

Country Status (24)

Country	Link
US (1)	US20130273157A1 (fr)
EP (1)	EP2658530A2 (fr)
JP (1)	JP2014501224A (fr)
KR (1)	KR20140007364A (fr)
CN (1)	CN103402500A (fr)
AR (1)	AR084610A1 (fr)
AU (1)	AU2011350396A1 (fr)
BR (1)	BR112013014875A2 (fr)
CA (1)	CA2823166C (fr)
CL (1)	CL2013001793A1 (fr)
CO (1)	CO6731132A2 (fr)
CR (1)	CR20130327A (fr)
EA (1)	EA028217B1 (fr)
EC (1)	ECSP13012718A (fr)
MA (1)	MA34768B1 (fr)
MX (1)	MX2013007588A (fr)
PE (1)	PE20141115A1 (fr)
PH (1)	PH12013501391A1 (fr)
SG (2)	SG190905A1 (fr)
TN (1)	TN2013000220A1 (fr)
TW (1)	TW201304823A (fr)
UY (1)	UY33841A (fr)
WO (1)	WO2012091153A2 (fr)
ZA (1)	ZA201304617B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2254556A2 (fr)	2008-03-11	2010-12-01	Takeda Pharmaceutical Company Limited	Préparation solide orodispersible
ES2790358T3 (es)	2011-12-28	2020-10-27	Global Blood Therapeutics Inc	Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
PT3738434T (pt)	2011-12-28	2023-11-13	Global Blood Therapeutics Inc	Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
GB201303781D0 (en)	2013-03-04	2013-04-17	Gauthier Pierre Pascal	Oral timer device and method of using same
EA037091B1 (ru)	2013-03-15	2021-02-04	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
MX378131B (es)	2013-03-15	2025-03-10	Global Blood Therapeutics Inc	Compuestos y sus usos para modular la hemoglobina.
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EA034922B1 (ru)	2013-03-15	2020-04-07	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
EP3102208B2 (fr)	2014-02-07	2024-07-17	Global Blood Therapeutics, Inc.	Polymorphe cristallin de la base libre de 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
KR20170083535A (ko)	2014-11-14	2017-07-18	젬파이어 세러퓨틱스 인코포레이티드	α,ω-다이카복실산-말단 다이알케인 에터를 제조하기 위한 방법 및 중간체
EP3288556A4 (fr)	2015-04-29	2018-09-19	Dexcel Pharma Technologies Ltd.	Compositions à désintégration par voie orale
MA43373A (fr)	2015-12-04	2018-10-10	Global Blood Therapeutics Inc	Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
TWI752307B (zh)	2016-05-12	2022-01-11	美商全球血液治療公司	新穎化合物及製造化合物之方法
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
TWI778983B (zh) *	2016-10-12	2022-10-01	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
AR111786A1 (es) *	2017-05-11	2019-08-21	Gemphire Therapeutics Inc	Composiciones de gemcabeno y su uso
US11696893B2 (en) *	2017-07-10	2023-07-11	Takeda Pharmaceutical Company Limited	Preparation comprising vonoprazan
CN108576205B (zh) *	2018-03-22	2022-01-04	湖北省农业科学院农产品加工与核农技术研究所	一种草莓联合干燥的处理方法
US11014884B2 (en)	2018-10-01	2021-05-25	Global Blood Therapeutics, Inc.	Modulators of hemoglobin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6150978A (ja)	1984-08-16	1986-03-13	Takeda Chem Ind Ltd	ピリジン誘導体およびその製造法
JPH072761B2 (ja)	1985-03-20	1995-01-18	不二パウダル株式会社	微結晶セルロ−ス球形顆粒及びその製造法
JPS62277322A (ja)	1986-02-13	1987-12-02	Takeda Chem Ind Ltd	安定化された腸溶性抗潰瘍固形組成物
FR2679451B1 (fr)	1991-07-22	1994-09-09	Prographarm Laboratoires	Comprime multiparticulaire a delitement rapide.
EP0553777B1 (fr)	1992-01-29	2002-04-24	Takeda Chemical Industries, Ltd.	Comprimé à dissolution rapide et sa fabrication
JP2919771B2 (ja)	1995-04-17	1999-07-19	佐藤製薬株式会社	速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤
JPH0948726A (ja)	1995-08-07	1997-02-18	Tanabe Seiyaku Co Ltd	口腔内速崩壊性製剤およびその製法
JP3828648B2 (ja)	1996-11-14	2006-10-04	武田薬品工業株式会社	２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en)	1996-11-14	2000-03-21	Takeda Chemical Industries Ltd	Method for producing crystals of benzimidazole derivatives
CA2587022A1 (fr)	1998-05-18	1999-11-25	Takeda Pharmaceutical Company Limited	Comprimes se desintegrant dans la bouche
US7399485B1 (en)	1998-07-28	2008-07-15	Takeda Pharmaceutical Company Limited	Rapidly Disintegrable solid preparation
TWI275587B (en)	1999-06-17	2007-03-11	Takeda Chemical Industries Ltd	A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6982275B2 (en)	2000-04-28	2006-01-03	Takeda Pharmaceutical Company Limited	Process for producing optically active sulfoxide derivative
CA2701704C (fr)	2000-05-15	2011-09-06	Takeda Pharmaceutical Company Limited	Procede de production d'un cristal
PL214684B1 (pl)	2000-12-01	2013-09-30	Takeda Pharmaceutical	Sposób wytwarzania krysztalów (R) lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu
JP4493970B2 (ja)	2002-10-16	2010-06-30	武田薬品工業株式会社	持続性製剤
EP1720527A2 (fr) *	2004-03-03	2006-11-15	Teva Pharmaceutical Industries Ltd	Composition pharmaceutique stable comprenant un medicament labile en milieu acide
CA2630235A1 (fr) *	2005-12-20	2007-07-12	Teva Pharmaceutical Industries Ltd.	Comprimes a desintegration orale de lansoprazole
US20070141151A1 (en) *	2005-12-20	2007-06-21	Silver David I	Lansoprazole orally disintegrating tablets
EP1837016A3 (fr) *	2006-03-08	2008-01-02	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique en multiple-unité
EP2098250B1 (fr) *	2006-12-28	2016-09-28	Takeda Pharmaceutical Company Limited	Préparation solide se désintégrant oralement
EP2254556A2 (fr) *	2008-03-11	2010-12-01	Takeda Pharmaceutical Company Limited	Préparation solide orodispersible
US20100015239A1 (en) *	2008-07-17	2010-01-21	Ahmed Salah U	Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same

2011
- 2011-12-26 WO PCT/JP2011/080568 patent/WO2012091153A2/fr active Application Filing
- 2011-12-26 SG SG2013040944A patent/SG190905A1/en unknown
- 2011-12-26 PH PH1/2013/501391A patent/PH12013501391A1/en unknown
- 2011-12-26 EP EP11811174.9A patent/EP2658530A2/fr not_active Withdrawn
- 2011-12-26 JP JP2013529237A patent/JP2014501224A/ja active Pending
- 2011-12-26 TW TW100148775A patent/TW201304823A/zh unknown
- 2011-12-26 EA EA201390981A patent/EA028217B1/ru not_active IP Right Cessation
- 2011-12-26 BR BR112013014875A patent/BR112013014875A2/pt active Search and Examination
- 2011-12-26 AU AU2011350396A patent/AU2011350396A1/en not_active Abandoned
- 2011-12-26 KR KR1020137019795A patent/KR20140007364A/ko not_active Withdrawn
- 2011-12-26 SG SG10201602311XA patent/SG10201602311XA/en unknown
- 2011-12-26 CA CA2823166A patent/CA2823166C/fr active Active
- 2011-12-26 MX MX2013007588A patent/MX2013007588A/es not_active Application Discontinuation
- 2011-12-26 UY UY0001033841A patent/UY33841A/es not_active Application Discontinuation
- 2011-12-26 PE PE2013001471A patent/PE20141115A1/es not_active Application Discontinuation
- 2011-12-26 CN CN2011800685821A patent/CN103402500A/zh active Pending
- 2011-12-26 US US13/997,862 patent/US20130273157A1/en not_active Abandoned
- 2011-12-27 AR ARP110104955A patent/AR084610A1/es unknown
2013
- 2013-05-24 TN TNP2013000220A patent/TN2013000220A1/fr unknown
- 2013-06-19 CL CL2013001793A patent/CL2013001793A1/es unknown
- 2013-06-21 ZA ZA2013/04617A patent/ZA201304617B/en unknown
- 2013-06-25 EC ECSP13012718 patent/ECSP13012718A/es unknown
- 2013-06-27 CR CR20130327A patent/CR20130327A/es not_active Application Discontinuation
- 2013-06-28 MA MA36063A patent/MA34768B1/fr unknown
- 2013-07-25 CO CO13176405A patent/CO6731132A2/es unknown

Also Published As

Publication number	Publication date
ECSP13012718A (es)	2013-12-31
EP2658530A2 (fr)	2013-11-06
UY33841A (es)	2012-07-31
WO2012091153A2 (fr)	2012-07-05
CA2823166A1 (fr)	2012-07-05
TW201304823A (zh)	2013-02-01
PH12013501391A1 (en)	2013-08-28
SG190905A1 (en)	2013-07-31
KR20140007364A (ko)	2014-01-17
EA028217B1 (ru)	2017-10-31
CN103402500A (zh)	2013-11-20
AU2011350396A1 (en)	2013-07-11
CR20130327A (es)	2013-08-22
MX2013007588A (es)	2013-08-09
CO6731132A2 (es)	2013-08-15
JP2014501224A (ja)	2014-01-20
BR112013014875A2 (pt)	2016-10-18
EA201390981A1 (ru)	2014-07-30
SG10201602311XA (en)	2016-04-28
CA2823166C (fr)	2019-04-09
PE20141115A1 (es)	2014-09-12
ZA201304617B (en)	2014-08-27
AR084610A1 (es)	2013-05-29
MA34768B1 (fr)	2013-12-03
WO2012091153A3 (fr)	2012-09-07
CL2013001793A1 (es)	2013-12-06
US20130273157A1 (en)	2013-10-17

Publication	Publication Date	Title
TN2013000220A1 (en)	2014-11-10	Orally disintegrating tablet
JP2010270128A5 (fr)	2011-12-01
NZ591688A (en)	2012-10-26	Dosage form comprising time-pulsatile release beads
RU2015110824A (ru)	2016-10-20	Фармацевтическая или нутрицевтическая композиция с замедленным высвобождением и стойкостью к воздействию этанола
NZ588499A (en)	2013-01-25	Controlled-release particles with core comprising a weakly basic drug and a controlled-release coating
JP2013522219A5 (fr)	2014-04-24
RU2014131238A (ru)	2016-02-20	Состав с отсроченным высвобождением для уменьшения частоты мочеиспускания и способ его применения
WO2011107855A3 (fr)	2012-03-29	Forme dosifiée sous forme de suspension liquide à libération prolongée pour une administration par voie orale
NZ595691A (en)	2013-06-28	Drug delivery composition
PE20091620A1 (es)	2009-11-12	Preparacion solida de desintegracion oral
JP2015506359A5 (fr)	2015-04-23
MX2013006247A (es)	2014-01-31	Tableta oralmente desintegradora.
NZ605601A (en)	2014-11-28	Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
WO2009043926A3 (fr)	2009-10-15	Comprimés oraux à désintégration rapide
JP2013529637A5 (fr)	2014-08-07
RU2014127884A (ru)	2016-02-10	Способы лечения сердечно-сосудистого нарушения
KR20160010595A (ko)	2016-01-27	구강내 붕괴정
EA031255B1 (ru)	2018-12-28	Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
EP2641594B1 (fr)	2017-02-01	Compositions pharmaceutiques solides gastro-résistantes enrobées pour inhibiteurs de pompe à protons
AR102228A1 (es)	2017-02-15	Una formulación de metformina de liberación sostenida y un método de preparación de la misma
NZ599742A (en)	2013-11-29	Improved oral pharmaceutical solid dosage form
WO2014086857A1 (fr)	2014-06-12	Composition pharmaceutique orale comprenant de l'étéxilate de dabigatran
CA2797809A1 (fr)	2011-11-03	Comprime a delitage intestinal
CN103751137B (zh)	2015-06-10	雷诺嗪多单元缓释微丸片
BR112015023381A2 (pt)	2017-07-18	composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido